Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Ono Pharmaceutical Co., Ltd. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 distinct examiners and 4 distinct art units, indicating that one examiner and one art unit handle more than one action while the remaining assignments are separate.
CHATTIN, AMY MARIE is the busiest examiner, with 2 pending actions. Those matters may benefit from coordinated review of claim language and response positions, while the other actions require examiner-specific preparation.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTTER, GILLIAN A | 1 | 54.5% | +46.0% |
| CHATTIN, AMY MARIE | 1 | 72.2% | +45.7% |
| SOROUSH, ALI | 1 | 46.7% | +30.9% |
| HADDAD, MAHER M | 1 | 50.6% | +53.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18744303 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | HUTTER, GILLIAN A | — |
| 18566424 | CANCER TREATMENT METHOD BY COMBINED USE OF CD47 INHIBITORY SUBSTANCE, IMMUNE CHECKPOINT INHIBITORY SUBSTANCE, AND STANDARD THERAPY | CHATTIN, AMY MARIE | — |
| 16753159 | BISPECIFIC ANTIBODY | HADDAD, MAHER M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18744303 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | HUTTER, GILLIAN A | — |
| 18566424 | CANCER TREATMENT METHOD BY COMBINED USE OF CD47 INHIBITORY SUBSTANCE, IMMUNE CHECKPOINT INHIBITORY SUBSTANCE, AND STANDARD THERAPY | CHATTIN, AMY MARIE | — |
| 17925934 | AGENT FOR PROTECTING AND/OR REGENERATING NEUROMUSCULAR JUNCTION | SOROUSH, ALI | — |
| 16753159 | BISPECIFIC ANTIBODY | HADDAD, MAHER M | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1643 | 1 |
| 1614 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18744303 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | HUTTER, GILLIAN A | 1625 | §102§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18566424 | CANCER TREATMENT METHOD BY COMBINED USE OF CD47 INHIBITORY SUBSTANCE, IMMUNE CHECKPOINT INHIBITORY SUBSTANCE, AND STANDARD THERAPY | CHATTIN, AMY MARIE | 1643 | §102§103§112 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 17925934 | AGENT FOR PROTECTING AND/OR REGENERATING NEUROMUSCULAR JUNCTION | SOROUSH, ALI | 1614 | §103 | Non-Final OA | — | Pending | Nov 17, 2022 |
| 16753159 | BISPECIFIC ANTIBODY | HADDAD, MAHER M | 1641 | §103§112 | Final Rejection | — | Pending | Apr 02, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOno Pharmaceutical Co., Ltd. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Gillian A Hutter has the most, with 1 of Ono Pharmaceutical Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
